Product News

Share this article:

UCB received FDA approval on a new indication for Cimzia, an injectable tumor necrosis factor (TNF) blocker. Cimzia is now indicated for moderate to severe rheumatoid arthritis, in addition to its prior indication for Crohn's disease. Cimzia will compete other TNF blockbusters such as Abbott's Humira, Johnson & Johnson's Remicade and Wyeth/Amgen's Enbrel.

 

Takeda received an FDA nod for an extended release version of its combo med Actoplus Met: Actoplus Met XR. Actoplus Met and Actoplus Met XR are indicated for the treatment of type 2 diabetes.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.